Epothilones in the treatment of cancer

Area of Science:

• Oncology
• Pharmacology

Background:

• Epothilones are cytotoxic macrolides with a mechanism of action similar to paclitaxel.
• They offer potential activity in taxane-resistant cancer models.
• Several epothilones (ixabepilone, patupilone, BMS-310705, KOS-862, ZK-EPO) are in early clinical trials.

Purpose of the Study:

• To review the clinical development and efficacy of epothilones in cancer treatment.
• To assess the activity of epothilones in both taxane-sensitive and taxane-refractory tumors.
• To identify the dose-limiting toxicities associated with epothilone therapy.

Main Methods:

• Review of Phase I and Phase II clinical trial data for epothilones.
• Analysis of efficacy in various cancer types, including breast, lung, prostate, and ovarian cancers.
• Evaluation of toxicities, such as neurotoxicity, neutropenia, and diarrhea.

Main Results:

• Significant activity observed in taxane-sensitive tumors like breast, lung, and prostate cancers.
• Modest response rates in taxane-refractory metastatic breast cancer.
• Promising efficacy demonstrated by ixabepilone and patupilone in hormone-refractory metastatic prostate cancer and taxane-refractory ovarian cancer.
• Dose-limiting toxicities in Phase I studies primarily included neurotoxicity and neutropenia, with diarrhea noted for patupilone.

Conclusions:

• Epothilones represent a promising class of agents for cancer treatment, particularly in taxane-resistant settings.
• Ixabepilone and patupilone show notable efficacy in specific refractory cancer types.
• Further investigation into epothilone therapy is warranted given their potential clinical benefit.